TY - JOUR
T1 - Efficacy and safety of the PD-1/PD-L1 in metastasic non-small cell lung cancer (NSCLC)
AU - González-Vélez, Abel
AU - Pino-Villareal, Luis E.
AU - Barrera-Barinas, Alexander
AU - Castillo-Niuman, Andrea
AU - Tolosa-Pérez, Erica N.
AU - Castelblanco, Diana I.
AU - Pinzón-Florez, Carlos E.
AU - Yomayusa, Nancy
N1 - Publisher Copyright:
© 2021 Publicaciones Permanyer. All rights reserved.
PY - 2021
Y1 - 2021
N2 - Lung cancer is the leading cause of death due to cancer worldwide; representing 18.4% of cancer mortality.Taking into account the impact of this pathology and the increase in the tendency of using immune checkpoint inhibitors PD-1/PD-L1 for the treatment of non-small cell lung cancer (NSCLC), a brief review was conducted of the evidence that evaluates the efficacy and safety of these drugs. Finding that there is a benefit in using immune checkpoint inhibitors PD-1/PD-L1 for the treatment of patients with metastatic NSCLC evaluated by overall survival, progression-free survival and adverse effects when used as monotherapy compared to chemotherapy. Although in combination therapy the adverse effects are increased when compared to chemotherapy without immunotherapy. In addition, some predictive factors of hyperprogressive disease have been found, which can be used to identify patients who will not benefit from immune therapy, although there is room for further investigation.
AB - Lung cancer is the leading cause of death due to cancer worldwide; representing 18.4% of cancer mortality.Taking into account the impact of this pathology and the increase in the tendency of using immune checkpoint inhibitors PD-1/PD-L1 for the treatment of non-small cell lung cancer (NSCLC), a brief review was conducted of the evidence that evaluates the efficacy and safety of these drugs. Finding that there is a benefit in using immune checkpoint inhibitors PD-1/PD-L1 for the treatment of patients with metastatic NSCLC evaluated by overall survival, progression-free survival and adverse effects when used as monotherapy compared to chemotherapy. Although in combination therapy the adverse effects are increased when compared to chemotherapy without immunotherapy. In addition, some predictive factors of hyperprogressive disease have been found, which can be used to identify patients who will not benefit from immune therapy, although there is room for further investigation.
KW - Non-small-cell lung carcinoma. Lung neoplasms. Programmed death-ligand 1 (PD-L1). Immunotherapy. Hyperprogressive disease
UR - http://www.scopus.com/inward/record.url?scp=85108800640&partnerID=8YFLogxK
U2 - 10.24875/j.gamo.21000005
DO - 10.24875/j.gamo.21000005
M3 - Artículo de revisión
AN - SCOPUS:85108800640
SN - 1665-9201
VL - 20
SP - 1
EP - 13
JO - Gaceta Mexicana de Oncologia
JF - Gaceta Mexicana de Oncologia
IS - 2
ER -